Significance of the Hemorrhagic Site for Recurrent Bleeding

Jun Takahashi(Iwate Medical University), Takeshi Funaki(Iwate Medical University), Kiyohiro Houkin(Iwate Medical University), Tooru Inoue(Iwate Medical University), Kuniaki Ogasawara(Iwate Medical University), Jyoji Nakagawara(Iwate Medical University), Satoshi Kuroda(Iwate Medical University), Keisuke YAMADA(Iwate Medical University), Susumu Miyamoto(Iwate Medical University), the JAM Trial Investigators, Takashi Yoshimoto(Hashimoto Municipal Hospital), Nobuo Hashimoto(Tohoku University), Ichiro Tsuji(Tohoku University), Yasutake Tomata(Tohoku University), Tsuguya Fukui(St. Luke's International Hospital), Yasushi Okada(National Kyushu Medical Center), Masayasu Matsumoto, Tsuguya Fukui(St. Luke's International Hospital), Ichiro Tsuji(Tohoku University), Yasuo Fukuuchi, Takashi Ohmoto, Yasuo Kuwabara(Izumi City General Hospital), Izumi Nagata(Chiba University), Junichi Ono(Chiba University), Toshio Machida(Chiba University), Ryuji Sakakibara(Chiba University), Kanji Yamane(Chugoku Rosai Hospital), Shinji OKITA(Chugoku Rosai Hospital), Kiyoshi Kumano(Chugoku Rosai Hospital), Toru Iwama(Gifu University), Yasuhiko Kaku(Gunma University), Nobuhito Saito(Gunma University), Hidenao Fukuyama(Hokkaido University), Ichiro Yabe(Hokkaido University), Fumio Moriwaka(Iwate Medical University), Akira Ogawa(Iwate Medical University), Kenji Yoshida(Iwate Medical University), Kiyotaka Fujii(Kitasato University), Masaru Yamada(Satou Hospital), Kimitoshi Sato(Kitasato University), Tsugio Akutsu(Kurashiki Central Hospital), Sen Yamagata(Kurashiki Central Hospital), Shigekazu Takeuchi(Izumi City General Hospital), Izumi Nagata(Hayashi Eye Hospital), Kentarō Hayashi(Nagasaki University), Nobutaka Horie(Nagoya City University), Kazuo Yamada(Kyoto University), Hiroyuki Katano(Nagoya City University), Atsuo Masago(Nagoya City University), Toshiaki Osato(Nakamura Memorial Hospital), Toshiichi Watanabe(Nakamura Memorial Hospital), Kaori Honjo(Nakamura Memorial Hospital), Kazuya Sako(Nakamura Memorial Hospital), Hiroyuki Nakase(Nara Medical University), Shoichiro Kawaguchi(Nara Medical University), Fumihiko Nishimura(Nara Medical University), Junichi Yamao(National Cerebral and Cardiovascular Center), Hiroaki Naritomi(National Kyushu Medical Center), Yasushi Okada(National Kyushu Medical Center), Hiroshi Abe(Suzuki (Japan)), Akifumi Suzuki(Research Institute for Brain and Blood Vessels Akita), Tatsuya Ishikawa(Tenri Hospital), Yoshinori Akiyama(Tenri Hospital), Toshihiko Suenaga(Tohoku University), Teiji Tominaga(Tohoku University), Miki Fujimura(Tohoku University), Shinji Nagahiro(Tokushima University), Masaaki Uno(Tokushima University), Kyoko Nishi(Tokushima University), Junichiro Satomi(Tokyo Women's Medical University), Yoshikazu Okada(National Kyushu Medical Center), Akitsugu Kawashima(Yamaguchi University), Koji Yamaguchi(Tokyo Women's Medical University), Tatsuya Ishikawa(Research Institute for Brain and Blood Vessels Akita), Takakazu Kawamata(Tokyo Women's Medical University), Yukiko Tsutsumi(Tokyo Women's Medical University)
Stroke
December 9, 2015
Cited by 139Open Access
Full Text

Abstract

BACKGROUND AND PURPOSE: The primary results of the Japan Adult Moyamoya Trial revealed the statistically marginal superiority of bypass surgery over medical treatment alone in preventing rebleeding in moyamoya disease. The purpose of this analysis is to test the prespecified subgroup hypothesis that the natural course and surgical effects vary depending on the hemorrhagic site at onset. METHODS: The hemorrhagic site, classified as either anterior or posterior, was the only stratifying variable for randomization. Statistical analyses were focused on the assessment of effect modification according to the hemorrhagic site and were based on tests of interaction. RESULTS: Of 42 surgically treated patients, 24 were classified as anterior hemorrhage and 18 as posterior hemorrhage; of 38 medically treated patients, 21 were classified as anterior and 17 as posterior. The hazard ratio of the primary end points (all adverse events) for the surgical group relative to the nonsurgical group was 0.07 (95% confidence interval, 0.01-0.55) for the posterior group, as compared with 1.62 (95% confidence interval, 0.39-6.79) for the anterior group (P=0.013 for interaction). Analysis within the nonsurgical group revealed that the incidence of the primary end point was significantly higher in the posterior group than in the anterior group (17.1% per year versus 3.0% per year; hazard ratio, 5.83; 95% confidence interval, 1.60-21.27). CONCLUSIONS: Careful interpretation of the results suggests that patients with posterior hemorrhage are at higher risk of rebleeding and accrue greater benefit from surgery, subject to verification in further studies. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr/index.htm. Unique identifier: C000000166.


Related Papers

No related papers found

Powered by citation graph analysis